In hypoxic ovarian cancer cells, FV-429 can interfere with the expression and phosphorylation of c-Scr, inhibit the translocation and DNA binding activity of STAT3, and inhibit HIF-1α expression, causing the downregulation of HK2 and VEGF and enhancement of the G2/M arrest induced by paclitaxel (117) (Figure 4). Here, HK2 is linked to ovarian carcinoma.